History

2003 NordMedica is founded by two senior executives with several years of international management experience from research based pharmaceutical companies, like Merck Sharpe and Dohme, Upjohn, Bayer and AstraZeneca.
2005 6 proprietary products are acquired from Eli Lilly, US for Denmark and Iceland. Keflex®, Kefzol®, Nebcina®, Doloxene®, Vancocin® and Dobutrex®.
2006 Vancocin® is acquired from Eli Lilly, US for the Swedish market.
2006 Neostigmin is acquired from Pfizer, US for the Swedish market.
2007 5 products are acquired from Pfizer for Sweden. Vibramycin®, Terramycin® with Polymyxin B, flurablastin, Adriamycin®, chloramphenicol succinat. Vibramycin® Oral suspension is also acquired for Norway, Finland, The Netherlands, Belgium and Luxembourg.
2007 Pondocillin® is acquired for Denmark from Leo Pharma, Denmark.
2008 Amekrin®/Amsidyl®/Amsidine® is acquired from Pfizer for Sweden, Germany, Switzerland, The Netherlands, Belgium and Luxembourg. Further rights for Amecrin in “compassionate use” for several international markets.
2008 Flurablastin and Adriamycin® is divested to Strides Arcolab and Vancocin® i.v. is divested to Farma Plus, Norway.
2008 Ampicillin is acquired for Denmark from Vepidan, Denmark.
2008 NordMedica SA is established as a principal subsidiary in Lugano, Switzerland. Managing Director for the company employed.
2009 FarmaPlus establishes their own distribution in Denmark after 4 successful years of collaboration with NordMedica.
2009 The market authorisation for Nebcina® is transferred to Eurocept International B.V., The Netherlands.
2009 NordMedica completes the acquisition of the product Estradurin® (polyestradiol) from Pfizer for 11 European countries.
2010 A Nordic product portfolio of 8 products - Ampicillin, Dobutrex®, Doloxene®, Keflex®, Kefzol®, Neostigmin®, Pondocillin®, and Vancocin® - is divested to Pharmacodane ApS, a subsidiary of German STADA Arzneimittel AG.
2010 The NordMedica headquarter is successfully relocated to Jægersborg Allé 164, 2820 Gentofte, Denmark.
2011 NordMedica A/S acquires worldwide rights to RescueFlow® from BioPhausia AB, Sweden. RescueFlow® (7.5% sodium chloride and 6% dextran 70) is a novel Small Volume Resuscitation drug.
2011 An agreement is signed with Goldshield Group Ltd, Surrey, UK by which the British and the Irish MA for Amsidine® is transferred to NordMedica. Goldshield will continue to act as distributor for Amsidine® in the 2 countries.
2011 At a Board of Directors Meeting it is decided for NordMedica A/S to acquire a majority shareholding in the Danish company CCURE A/S from Chr. Olesen & Co. A/S. CCURE A/S is a pharmaceutical development company focused on bringing a range of basic pharmaceutical products to market in prefilled syringes. www.ccurepharma.com
2011 The veterinary product rights for Doxynord® Vet is divested to Let Vet Pharma BV, The Netherlands.
2011 NordMedica aquired a Danish portfolio of 5 well established products from Amgros (The Danish Regions' Pharmaceutical Organisation).
2012 A Nordic distribution agreement for Methylthioninium chloride Proveblue, was signed with French ProvePharm S.A.S.
2012 NordMedica A/S divested all products to NordMedica International A/S as per July 1st, 2012, except for the product AMEKRIN®/ AMSIDYL®/ AMSIDINE®.
2012 A Nordic and Baltic distribution agreement for Xaluprine® Oral Suspension 20mg/ml was signed with Trimedica Ltd., United Kingdom.

Copyright © NordMedica A/S, All Rights Reserved.